Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The product is expected to be launched in FY25
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Subscribe To Our Newsletter & Stay Updated
